Sorrento Therapeutics, Inc.
生物技术研究
San Diego,California 15,917 位关注者
Transforming Science into Saving Life™ Medicine
关于我们
Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
- 网站
-
http://www.sorrentotherapeutics.com
Sorrento Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- San Diego,California
- 类型
- 上市公司
- 创立
- 2009
- 领域
- Biopharma、cancer、COVID-19、Diagnostics、infectious diseases和Non-opioid pain management